226 related articles for article (PubMed ID: 23579220)
1. Rare BRAF mutations in melanoma patients: implications for molecular testing in clinical practice.
Heinzerling L; Kühnapfel S; Meckbach D; Baiter M; Kaempgen E; Keikavoussi P; Schuler G; Agaimy A; Bauer J; Hartmann A; Kiesewetter F; Schneider-Stock R
Br J Cancer; 2013 May; 108(10):2164-71. PubMed ID: 23579220
[TBL] [Abstract][Full Text] [Related]
2. Comparison of high resolution melting analysis, pyrosequencing, next generation sequencing and immunohistochemistry to conventional Sanger sequencing for the detection of p.V600E and non-p.V600E BRAF mutations.
Ihle MA; Fassunke J; König K; Grünewald I; Schlaak M; Kreuzberg N; Tietze L; Schildhaus HU; Büttner R; Merkelbach-Bruse S
BMC Cancer; 2014 Jan; 14():13. PubMed ID: 24410877
[TBL] [Abstract][Full Text] [Related]
3. BRAF mutation screening in melanoma: is sentinel lymph node reliable?
Nardin C; Puzenat E; Prétet JL; Algros MP; Doussot A; Puyraveau M; Mougin C; Aubin F
Melanoma Res; 2015 Aug; 25(4):328-34. PubMed ID: 26020488
[TBL] [Abstract][Full Text] [Related]
4. Molecular platforms utilized to detect BRAF V600E mutation in melanoma.
Curry JL; Torres-Cabala CA; Tetzlaff MT; Bowman C; Prieto VG
Semin Cutan Med Surg; 2012 Dec; 31(4):267-73. PubMed ID: 23174497
[TBL] [Abstract][Full Text] [Related]
5. Mutation landscape in melanoma patients clinical implications of heterogeneity of BRAF mutations.
Heinzerling L; Baiter M; Kühnapfel S; Schuler G; Keikavoussi P; Agaimy A; Kiesewetter F; Hartmann A; Schneider-Stock R
Br J Cancer; 2013 Nov; 109(11):2833-41. PubMed ID: 24196789
[TBL] [Abstract][Full Text] [Related]
6. Multisite analytic performance studies of a real-time polymerase chain reaction assay for the detection of BRAF V600E mutations in formalin-fixed, paraffin-embedded tissue specimens of malignant melanoma.
Anderson S; Bloom KJ; Vallera DU; Rueschoff J; Meldrum C; Schilling R; Kovach B; Lee JR; Ochoa P; Langland R; Halait H; Lawrence HJ; Dugan MC
Arch Pathol Lab Med; 2012 Nov; 136(11):1385-91. PubMed ID: 22332713
[TBL] [Abstract][Full Text] [Related]
7. BRAF-V600 Mutation Heterogeneity in Primary and Metastatic Melanoma: A Study With Pyrosequencing and Immunohistochemistry.
Yaman B; Kandiloğlu G; Akalin T
Am J Dermatopathol; 2016 Feb; 38(2):113-20. PubMed ID: 26630683
[TBL] [Abstract][Full Text] [Related]
8. BRAF inhibitor activity in V600R metastatic melanoma.
Klein O; Clements A; Menzies AM; O'Toole S; Kefford RF; Long GV
Eur J Cancer; 2013 Mar; 49(5):1073-9. PubMed ID: 23237741
[TBL] [Abstract][Full Text] [Related]
9. Detection of BRAF V600 mutations in metastatic melanoma: comparison of the Cobas 4800 and Sanger sequencing assays.
Qu K; Pan Q; Zhang X; Rodriguez L; Zhang K; Li H; Ho A; Sanders H; Sferruzza A; Cheng SM; Nguyen D; Jones D; Waldman F
J Mol Diagn; 2013 Nov; 15(6):790-5. PubMed ID: 23994118
[TBL] [Abstract][Full Text] [Related]
10. Sensitive allele-specific real-time PCR test for mutations in BRAF codon V600 in skin melanoma.
Pisareva E; Gutkina N; Kovalenko S; Kuehnapfel S; Hartmann A; Heinzerling L; Schneider-Stock R; Lyubchenko L; Shamanin VA
Melanoma Res; 2014 Aug; 24(4):322-31. PubMed ID: 24922189
[TBL] [Abstract][Full Text] [Related]
11. BRAFp.V600E, p.V600K, and p.V600R Mutations in Malignant Melanoma: Do They Also Differ in Immunohistochemical Assessment and Clinical Features?
Ponti G; Tomasi A; Maiorana A; Ruini C; Maccaferri M; Cesinaro AM; Depenni R; Manni P; Gelsomino F; Giusti F; Garagnani L; Pellacani G
Appl Immunohistochem Mol Morphol; 2016 Jan; 24(1):30-4. PubMed ID: 26633701
[TBL] [Abstract][Full Text] [Related]
12. Clinical and therapeutic implications of BRAF mutation heterogeneity in metastatic melanoma.
Mesbah Ardakani N; Leslie C; Grieu-Iacopetta F; Lam WS; Budgeon C; Millward M; Amanuel B
Pigment Cell Melanoma Res; 2017 Mar; 30(2):233-242. PubMed ID: 28002643
[TBL] [Abstract][Full Text] [Related]
13. Allele frequencies of BRAFV600 mutations in primary melanomas and matched metastases and their relevance for BRAF inhibitor therapy in metastatic melanoma.
Satzger I; Marks L; Kerick M; Klages S; Berking C; Herbst R; Völker B; Schacht V; Timmermann B; Gutzmer R
Oncotarget; 2015 Nov; 6(35):37895-905. PubMed ID: 26498143
[TBL] [Abstract][Full Text] [Related]
14. A Japanese case of melanoma of unknown origin with a rare BRAF
Kuriyama H; Kimura T; Mizuhashi S; Nishimura Y; Kanemaru H; Kajihara I; Makino K; Aoi J; Matsui H; Fukushima S
Drug Discov Ther; 2022 Nov; 16(5):256-257. PubMed ID: 36273892
[TBL] [Abstract][Full Text] [Related]
15. Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma.
Long GV; Menzies AM; Nagrial AM; Haydu LE; Hamilton AL; Mann GJ; Hughes TM; Thompson JF; Scolyer RA; Kefford RF
J Clin Oncol; 2011 Apr; 29(10):1239-46. PubMed ID: 21343559
[TBL] [Abstract][Full Text] [Related]
16. Clinicopathological features and clinical outcomes associated with TP53 and BRAF
Kim DW; Haydu LE; Joon AY; Bassett RL; Siroy AE; Tetzlaff MT; Routbort MJ; Amaria RN; Wargo JA; McQuade JL; Kemnade J; Hwu P; Woodman SE; Roszik J; Kim KB; Gershenwald JE; Lazar AJ; Davies MA
Cancer; 2017 Apr; 123(8):1372-1381. PubMed ID: 27911979
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of BRAF mutation testing methodologies in formalin-fixed, paraffin-embedded cutaneous melanomas.
Lade-Keller J; Rømer KM; Guldberg P; Riber-Hansen R; Hansen LL; Steiniche T; Hager H; Kristensen LS
J Mol Diagn; 2013 Jan; 15(1):70-80. PubMed ID: 23159593
[TBL] [Abstract][Full Text] [Related]
18. Accurate detection of BRAF p.V600E mutations in challenging melanoma specimens requires stringent immunohistochemistry scoring criteria or sensitive molecular assays.
Fisher KE; Cohen C; Siddiqui MT; Palma JF; Lipford EH; Longshore JW
Hum Pathol; 2014 Nov; 45(11):2281-93. PubMed ID: 25228337
[TBL] [Abstract][Full Text] [Related]
19. A HRM assay for identification of low level BRAF V600E and V600K mutations using the CADMA principle in FFPE specimens.
Huebner C; Weber R; Lloydd R
Pathology; 2017 Dec; 49(7):776-783. PubMed ID: 29100713
[TBL] [Abstract][Full Text] [Related]
20. Tumor homogeneity between primary and metastatic sites for BRAF status in metastatic melanoma determined by immunohistochemical and molecular testing.
Boursault L; Haddad V; Vergier B; Cappellen D; Verdon S; Bellocq JP; Jouary T; Merlio JP
PLoS One; 2013; 8(8):e70826. PubMed ID: 23976959
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]